Jeffrey D. Bloss - 18 Mar 2026 Form 3 Insider Report for NuCana plc (NCNA)

Reporting relationship: Chief Medical Officer
Issuer ticker: NCNA
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 19 Mar 2026, 17:52:36 UTC
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ian Webster, Attorney-in-Fact for Jeffrey Bloss

Key filing fact

Jeffrey D. Bloss filed Form 3 for NuCana plc (NCNA) on 19 Mar 2026.

Key facts

This page summarizes Jeffrey D. Bloss's Form 3 filing for NuCana plc (NCNA).
0 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 19 Mar 2026, 17:52.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001807569 Primary reporting owner

Bloss Jeffrey D.

Relationship: Chief Medical Officer
Address: C/O NUCANA PLC, 3 LOCHSIDE WAY, EDINBURGH, UNITED KINGDOM
Signature: /s/ Ian Webster, Attorney-in-Fact for Jeffrey Bloss
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NCNA holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 47,136
Date: 18 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 73,079,440
Exercise price
Footnotes: F1

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 87,871,006
Exercise price
Footnotes: F2

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 146,158,880
Exercise price
Footnotes: F3

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 73,079,440
Exercise price
Footnotes: F4

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 87,871,006
Exercise price
Footnotes: F5

NCNA holding Derivative

Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 175,742,012
Exercise price
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The ordinary shares, nominal value 0.0004 Pounds Sterling per share (the "Ordinary Shares"), of NuCana plc (the "Company") underlying this option have an exercise price of 0.004 Pounds Sterling, completed vesting on June 20, 2025 and expire June 20, 2035.

Footnote F2

The Ordinary Shares underlying this option have an exercise price of 0.0005 Pounds Sterling, completed vesting on January 14, 2026 and expire January 14, 2036.

Footnote F3

The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest as to 25% on June 20, 2026, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Footnote F4

The Ordinary Shares underlying this option have an exercise price of 0.004 Pounds Sterling and will vest as to 25% on June 20, 2026, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Footnote F5

The Ordinary Shares underlying this option have an exercise price of 0.0005 Pounds Sterling and will vest as to 25% on January 14, 2027, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

Footnote F6

The Ordinary Shares underlying this option have an exercise price of 0.0004 Pounds Sterling and will vest as to 25% on January 14, 2027, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

SEC remarks

This Form 3 is being filed late due to unanticipated delays in receiving the Reporting Person's EDGAR codes, which delays the Reporting Person understands were due to the high volume of applications at the time. Exhibit 24.1 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .